A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. A prospective non-A, non-B follow-up program, implemented in a hepatitis B surface antigen-free dialysis unit, enabled us to report on the natural history of hepatitis C virus (HCV) infection in hemodialyzed patients between 1980 and 1992. For this program, every patient was prospectively monitored every two weeks for alanine amino transferase (ALT) activity, and every month for gammaglutamyl transpeptidase (GGT) activity and systematic collection of frozen sera. Sequences of stored sera from 217 patients were repeatedly tested for anti-HCV antibodies using second generation assays. Eighty-six of the 217 patients (39.6%), including 61 of the 67 patients with non-A, non-B hepatitis (91%), had HCV infection repeatedly evidenced by positive ELISA in all, and confirmed by RIBA in 84 of 86 (97.5%). In addition, 19 out of 23 patients (82.6%) were positive for HCV RNA by the polymerase chain reaction (PCR). Of the 86 anti-HCV positive patients, 41 had previously acquired HCV infection, and 45 seroconverted during chronic dialysis. Of these, all but one patient developed hepatitis with raised ALT activity which lasted for at least six months in all. Only 29 of 45 patients (64.5%) had a history of blood transfusion. Seventy-eight of the 86 patients (91%) who were followed up for one to 11.5 years (median 5) retained anti-HCV for several years. Nineteen liver biopsies performed in 16 patients showed chronic active hepatitis in 8 (50%) and hepatocellular carcinoma without cirrhosis in one patient. In most cases, the outcome of HCV infection was chronic, since 54 patients (69.2%) exhibited persistently elevated GGT and anti-HCV positivity combined with either abnormal or fluctuating ALT (30.8%) or normal ALT (38.4%), and 16 patients (20.5%) had persistently elevated anti-HCV titers. Resolutive hepatitis C was uncommon since only eight patients (10.3%) gradually lost their HCV markers. The incidence and cumulative risk of seroconversion only decreased after 1988 to 1990, when routine testing of the blood supply for surrogate markers and anti-HCV antibody was started in France. The incidence of post-transfusion hepatitis became nil in 1990 before that of nosocomial infection (1991). HCV prevalence also decreased, from 43.6 to 29.2%. In conclusion, HCV was responsible for 91% of non-A, non-B hepatitis cases. Hepatitis was identified as the primary HCV infection in all but one case. GGT activity emerged as a reliable marker of long-term HCV infection. The severity of the disease seems to correlate with the persistence of ALT and/or GGT changes, combined with that of anti-HCV and HCV RNA positivity. Transmission of HCV was both transfusional and nosocomial.
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HCV prophylaxis should now focus on the eradication of nosocomial infection.
After the identification of hepatitis C virus (HCV) as the major agent responsible for transfusion-associated non-A, non-B hepatitis [1-31, one of the important achievements resulting from the progress made in characterizing the HCV genome [4] was the introduction of second generation assays for the detection of antibodies to HCV, which clearly improved the identification of hepatitis C [5] .
This 12-year follow-up study of HCV infection is a secondary benefit from the program of prophylaxis against hepatitis B virus (HBV) implemented since the creation of our hospital's dialysis department. As soon as the program was enforced, this prophylaxis, which has proven effective from 1978 until now, facilitated the identification of non-A, non-B hepatitis. We therefore tracked down this new form of hepatitis, and since 1980 an individualized bank of frozen sera has been stored for all patients at monthly intervals. This serological material was immediately used for the preliminary anti-HCV testing in 1980 [6] , and then for the improved anti-HCV assays which became available in 1989. We report here the results of this long-term follow-up study, which is both prospective and retrospective, and focuses on the clinical and epidemiologic aspects of HCV infection in a single dialysis unit.
Methods
Since January 1, 1978, all patients admitted to our new pilot dialysis department, at the Centre Hospitalier Pasteur-ValleryRadot in Paris, AURA, France, have been enrolled in a prospective and preventive follow-up program against HBV infection in hemodialyzed patients. This program, based on the selection of patients negative for hepatitis B surface antigen (HBs Ag) and on the prospective follow-up of HBV serology, was soon combined with a program for the prospective detection of non-A, non-B hepatitis. To classify this recently identified hepatitis of undefined cause, particularly in hemodialyzed patients, we created, in 1980, an individualized bank of frozen sera prospectively stored at intervals of at least one month. We then waited until reliable HCV assays became available. We report here on the different clinical and epidemiologic patterns of HCV infection identified in our dialysis unit by this prospective program over a period of up to 12 years.
For the purpose of this study, carried out between January 1, 1980 and January 1, 1992, we selected 217 consecutive hemodialyzed patients who had been dialyzed in our facility for at least one whole year (range: ito 14 years). When anti-HCV testing became available, all these patients were tested for anti-HCV antibodies at yearly intervals for at least two consecutive years. The 217 patients included 124 who started dialysis in our unit, and 93 who had been previously dialyzed in other units. The follow-up program for each patient comprized measurements of serum alanine aminotransferase (ALT) and aspartate aminotransferase activity twice a month, and of alkaline phosphatase and gamma glutamyl transpeptidase (GGT) activity once a month. Whenever hepatitis was suspected, the interval between these measurements was shortened to a week for a month. In addition, sequences of frozen sera were collected and stored upon entry into the dialysis facility and subsequently at monthly intervals. Whenever biochemical hepatitis was suspected, the interval of collection was also shortened to a week for a month. Therefore, each patient completed an individualized clinical and serological follow-up which began at admission and stopped at one of the four end points: death, transplantation, transfer to another unit or the end of the period studied.
Non-A, non-B hepatitis was suspected if ALT activity rose to In all, 1772 selected samples corresponding to individual sequences from the 217 hemodialyzed patients were tested for HCV by second-generation anti-HCV enzyme immunoassay (ELISA 2, Ortho Diagnostic Systems, Raritan, New York, USA) at least once a year in case of anti-HCV negativity, but every month and even every week in case of anti-HCV positivity. A recombinant immunoblot assay (RIBA 2, Chiron Corporation, Emeryville, California, USA) was repeatedly used for samples positive by ELISA. The RIBA 2 assay uses four HCV antigens comprising the c22-3 core protein and the three non-structural proteins c33c, clOO-3 and 5-1-1. Samples reactive to at least two HCV antigen bands were considered RIBA positive, and samples reactive to only one band were considered indeterminate. In the absence of reactivity they were considered negative. Samples reactive by ELISA but negative by RIBA were considered anti-HCV negative.
Additional fresh sera from 23 anti-HCV patients, one of whom lost his anti-HCV positivity, were analyzed for HCV RNA after PCR amplification. PCR was performed according to the protocol previously described [7] , on recent fresh samples which were immediately separated from the clot using recommended procedures to avoid contamination. Southern blots were considered positive if they had the same apparent molecular weight as the positive control.
Epidemiological analysis
The annual incidence of HCV was taken as the ratio of the number of new seroconversions to HCV diagnosed each year to the number of person-years of exposure to the risk of HCV. The cumulative incidence was then calculated. Comparisons between groups were made by the chi-square method.
Results
Definition and frequency of events HCV infection affected 86 of the 217 patients tested (39.6%), as evidenced by repeated anti-HCV ELISA positivity (Fig. 1) ; 84 of 86 cases (97.5%) were confirmed by a positive RIBA and 2 of 86 were indeterminate.
Forty-one of these patients had anti-HCV antibodies present at entry in the unit. Thirty-four of them (83%) had been previously dialyzed in another unit and were positive for anti-HCV at transfer. The seven others were positive prior to initiation of dialysis; 4 of 7 came from North Africa, giving an infection rate of 21% for this geographic subgroup versus 1.5% for the others.
The other 45 patients, who were negative prior to initiation of dialysis and seroconverted during the course of chronic dialysis, developed primary HCV infection; 29 of 45 had a history of blood transfusion (64.5%) prior to conversion, 5 of 45 may have had other parenteral exposures, 4 of 45, all of whom were dialyzed on the same machine with closed circulation of dialysate, seroconverted to HCV within a two month period, and seven patients had no obvious risk factors.
Clinical and serological fratures of hepatitis C Sixty-seven patients were shown to have non-A, non-B hepatitis. Of these, 61(91%) ultimately proved to have antibodies to HCV; they included 45 patients with primary HCV infection and 19 previously infected patients (Fig. 1) .
The features of primary HCV infection were studied in 42 of the 45 patients who seroconverted to HCV during the course of chronic dialysis, since two of them had too short a follow-up and one seroconverted in the absence of hepatitis. The mean age of these patients (Table 1) was 50 years (range 26 to 77 years); 22 (5 1% ) were male; their initial nephropathy was not different from that of the other groups. The mean interval between the initial dialysis and the development of hepatitis was 41.2 months (range 1 to 147 months). The course of hepatitis C was not different in the post-transfusion cases, and in those in which it was probably acquired in the dialysis setting. The acute phase of the disease was mild in 7 patients and marked in the 35 others. Icterus or subicterus was present in 6 (14.3%). The pattern of ALT activity which revealed acute primary hepatitis C was variable. In the 7 mild cases (16.7%), hepatitis began by low fluctuating levels of ALT activity followed by a single peak which was delayed and moderate. The other patients exhibited one, two or three successive ALT peaks, usually at lower levels, separated by normal or abnormal ALT levels; the mean maximum ALT level was 357 lU/liter. In all the patients, hepatitis followed a chronic course, because elevated or fluctuating ALT values always lasted more than six months (range 6.25 months to 7 years).
In these cases of HCV seroconversion combined with hepatitis, the first samples positive by ELISA were negative, indeterminate and positive by RIBA in 2, 27 and 13 patients, respectively (5, 64 and 31%). RIBA 2 reactivity never preceded ELISA positivity, and sometimes remained indeterminate for periods ranging from one week to four years after seroconversion. Three temporal patterns could be distinguished: 21 patients (50%) had detectable ELISA positivity together with abnormal ALT in the same sample, but markedly elevated values were only found in 12 of them. In six other patients (14.3%), ELISA positivity preceded the first ALT increase by 0.5 to 1.5 months, whereas in the remaining 15 (35.7%) it only occurred one week to five months after the onset of hepatitis (mean 6 weeks).
The remaining 19 patients with pre-existing chronic hepatitis C also had biochemical hepatitis that resembled that observed in primary HCV infection, but at lower levels and with more frequent ALT fluctuations. All of them were clearly anti-HCV positive by RIBA.
Long-term follow-up study and outcome of HCV infection Seventy-eight of the 86 patients (9 1%) who were followed for at least a year after anti-HCV detection (median 5 years) were included in this study (Figs. 2 and 3) . After its appearance, (82.6%) had a positive assay, whereas the one patient who had lost anti-HCV antibodies was negative. While most patients did not have ALT activity characteristic of liver disease, 16 patients underwent 19 liver biopsies. Eight liver biopsies, performed within two years of infection onset, revealed discrete portal fibrosis or minimal changes in 6 cases, and chronic active hepatitis with cirrhosis in 2 alcoholic patients. The 11 other biopsies, performed between 3 and 13 years after anti-HCV detection, showed chronic active hepatitis in 6 patients, with cirrhosis in one and hepatocellular carcinoma in another after 9 and 11 years, respectively. The 2 patients who had iterative biopsies (2 and 3, respectively) evolved from discrete portal fibrosis to chronic active hepatitis six and seven years later.
After combining the overall data for 393 person-years of follow-up, we identified three distinct patterns for predicting the severity and infectiousness of the disease which developed in our dialysis patients (Figs. 2 and 3 ). The first pattern, which was very common (69.2%) correlated with the most severe and infectious form of the disease (Fig. 3 ). It applied to 54 patients who retained ALT and/or GGT changes: out of these 54 patients, 24 (30.8%) had either elevated or fluctuating ALT levels (Fig. 2, case 1 ), but the remaining 30 (38.4%) had normal ALT activity for two to seven years. Regardless of the ALT activity profile, all 54 patients exhibited serially elevated GGT activity (Fig. 2, cases 3 and 4) and confirmed RIBA in all but one case. Furthermore, this group included (Fig. 3 ) the 8 patients with histologically active hepatitis, and the one with hepatocellular carcinoma. In addition, 14 of 14 of the patients tested were positive for HCV RNA. The second less common pattern (Fig. 3 a Prevalence relates the total number of anti-HCV seropositive patients to the population tested b One half the total number of patients present at the beginning and end of the period C Same method as b but reduced to the calculated number of anti-HCV seronegative patients Relates the total number of seroconversions detected within a year to the total number of person-years at risk A calculation expressed by 1 -Exp
reflected by the loss of RIBA bands. The third pattern (Fig. 3) which included 8 patients was rare (10.3%). It seemed to correlate with resolutive hepatitis, as suggested by the combination of normal enzymatic activity with either complete clearance of HCV markers (Fig. 2, case 2) or gradual loss of RIBA bands and undetectable HCV RNA.
Natural epidemiologic history of HCV infection
From the early 1980's to January 1992, the prevalence and especially the incidence and cumulative risk of HCV infection clearly varied (Table 2 ). The rate of new infections decreased significantly after 1988 to 1990, when routine testing of the blood supply for surrogate markers (ALT and anti-HBc, 1988) and HCV antibodies (March 1990) were implemented in France. However, although seroconversion to HCV became nil in 1988 and 1991, we still identified one additional post-transfusion case in 1989, and more especially 4 cases of hepatitis C were certainly acquired in our dialysis setting in 1989 and 1990. On the other hand, even though the prevalence also decreased, its rate was still very high at the end of the study (29.2%).
The study of seroconversion versus time (Fig. 4) shows that in 1980, the first year of the study, seroconversion to HCV only occurred in patients who had a history of blood transfusion. This figure also shows that the consecutive yearly incidence of transfusion-associated HCV infection was variable and dropped over time, whereas that of nosocomial dialysis HCV infection remained relatively constant at 1.9% to 4.3% (ito 2 cases per year), except for the peak in 1981.
Residual hepatitis
Six of the 67 patients who had non-A, non-B hepatitis (9%) lacked HCV markers and were therefore classified as having non-A, non-B, non-C hepatitis. Hepatitis was mild in these six cases; its duration varied from one to four months in four patients and exceeded six months in two, Two of these six patients (33.3%) were immigrants from North Africa, and only three (50%) had a history of blood transfusion. In addition, 18 of the 131 HCVnegative patients had ALT fluctuations without meeting hepatitis criteria. By contrast, 107 of our patients without detectable HCV infection (81.7%) had constantly normal ALT and GGT activity in their follow-up samples.
Discussion
This prospective study of 217 hemodialyzed patients over a period of up to 12 years shows that HCV infection was very frequent in our dialysis population (39.6%), that virus C was responsible for 91% of non-A, non-B hepatitis cases and that hepatitis mostly revealed the primary HCV infection (42 of 43).
In the present study which began in 1980, diagnosis of HCV infection raised many doubts until the introduction of specific anti-HCV assays in 1989, because the ALT changes were even milder than those reported in nonimmunocompromised populations [2, 3, 8] . When specific anti-HCV testing became available, the results remarkably corroborated these enzymatic changes, even when they were minimal. The HCV infection was therefore clear, as evidenced by a positive ELISA (86 of 86) with either a positive RIBA (84 of 86) or an indeterminate RIBA (2 of 86).
However, our results underlined the difficulties of early diagnosis of primary HCV infection in hemodialyzed patients, including the identification of atypical seroconversion profiles such as slight, fluctuating or non-existent changes in ALT activity, delayed detection of anti-HCV, and long-term persistence of an isolated indeterminate RIBA preceding RIBA positivity.
The chronic course of hepatitis was most difficult to recognize, because elevated ALT activity was often interrupted by long periods of normal activity. This means that after the onset of hepatitis, the follow-up of HCV infection must be extremely meticulous and very prolonged. Using this approach, hepatitis had a chronic course in all our patients who seroconverted, and this frequency was higher than that reported in nonimmunocompromised populations [2, 3, [8] [9] [10] . Rapid progression of the liver disease was only observed in two patients with chronic alcoholism, as already reported [11] . By contrast, the long-term progression of the disease was more complex to define. The severity of HCV infection was not simply based on the ALT changes, which did not prove to be a reliable long-term marker of the disease, because patients with normal ALT activity had histologically active hepatitis. Importantly, all of them exhibited chronic GGT increase. Therefore, in our experience, GGT activity, which remained serially elevated long after the ALT level returned to normal, emerged as a pertinent marker for predicting the long-term severity of HCV infection. The overall incidence and prevalence of HCV infection varies widely among dialysis units all over the world [12] [13] [14] [15] [16] . This variation is likely due to multiple factors, including the care with which one attempts to identify cases, as well as the past transfusion practices of the unit. Although there were no data given regarding the transfusion history of the patients who transferred from other dialysis facilities, we identified two main distinct forms of HCV infection in our unit. Most of our patients derived their infection from transfusion with contaminated blood (64.5%). Historically, blood transfusion was the first identified source of HCV contamination, because the patients contaminated during the first year of the study were only those who had a history of blood transfusion and there were no cases of infection derived from other sources.
As recently reported [17] , it soon became evident that other risks of HCV infection existed in the dialysis setting. Thus, four patients who shared the same dialysis machine with closed circulation of dialysate seroconverted within a two month period. However, it was impossible to assert that any specific source was responsible for the spread in this outbreak, since multiple combined risk factors do exist in dialysis units, either from contaminated machines and/or from any other dialysis equipment and from the overall patient setting.
Finally, the sources of infection remained unknown for seven of our patients, for whom other causes of HCV spread could not be excluded [18] [19] [20] . HCV infection was already present prior to initiation of dialysis in seven of the 86 anti-HCV positive patients. This underlines the importance of starting HCV detection early in the management of kidney disease [21] .
As previously published [22, 23] , the decrease observed in the incidence of HCV since blood screening was started is encouraging. Combination of this screening with the recent reduction in the number of blood transfusion in our unit following the use of erythropoietin (1988) nosocomial infection must not be underestimated. It was only during the last year of the study (1992) that we failed to observe any new infection from any source. However, this does not mean that dialysis hepatitis has been eradicated, since anti-HCV positive patients should be considered infectious [24] [25] [26] [27] [28] unless one can document long-term clearance of HCV RNA. Thus, most of the present cases of this study were associated with evidence of chronic HCV infection. Since anti-HCV antibodies persisted for years, the yearly prevalence of HCV infection tended to decrease over time, but its rate was 29.2% at the end of our study. This means that there is still a permanent risk of HCV spread in the dialysis setting. Consequently, we should recommend rigorous enforcement of multiple basic measures. These prophylactic measures should include the removal of dialysis machines with closed circulation of dialysate, the universal use of disposable materials and of efficacious disinfectants, the rigorous cleaning of each patient setting between dialysis sessions, and the reinforcement of meticulous health care precautions.
Since the effects of immunoprophylaxis have not yet been clearly defined [29, 30] , the current tracking of HCV infection should be encouraged together with the extension of such nonspecific prophylactic methods until a vaccine becomes available. These measures, combined with the treatment of the chronic and even acute phases of the disease [31, 32] should reduce the rate of HCV infection in dialysis units. By contrast, if HCV infection persists despite these efforts, even at a low rate, the development of distinct units will have to be considered to avoid contaminating additional hemodialyzed patients.
In conclusion, HCV was responsible for 91% of dialysisassociated non-A, non-B hepatitis cases among our hemodialyzed patients. HCV infection in these patients was chronic in nearly 90% of cases. Transmission of HCV infection in the dialysis setting was both transfusional and nosocomial. HCV prophylaxis should now focus on the eradication of nosocomial infection, which in the absence of specific prophylaxis will require very meticulous precautions.
